8-K current report · filed Nov 2, 2026

CRISPR Therapeutics AG (CRSP) 8-K Current Report: November 2, 2026

Item 2.02Item EX-99.1CRSP overview

Short answer

CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026 announced.

CRISPR Therapeutics AG 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Business highlights included alongside quarterly results
  • Full financial details and operating updates available in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • CASGEVY revenue $99 million, up 30% quarter-over-quarter and nearly sixfold year-over-year, validating accelerating commercial adoption
  • More than 750 patients initiated CASGEVY treatment worldwide, with approvals expanding to younger children in additional markets
  • CTX310 received two FDA RMAT designations, potentially enabling accelerated development, review, and approval pathways
  • Cash, equivalents, and marketable securities $2,276.6 million, bolstered by $585.4 million convertible-note proceeds and supporting pipeline investment
  • Net loss $111.4 million versus $106.4 million, while R&D increased to $71.9 million and collaboration expense declined to $41.3 million

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CRISPR Therapeutics AG 8-K filings

Get the next CRSP 8-K as it lands

Follow CRSP for push alerts, or ask the research agent what this filing means.